| Literature DB >> 33602930 |
Maria Xydia1,2, Raheleh Rahbari3, Eliana Ruggiero4, Iain Macaulay3,5, Maxime Tarabichi3,6, Robert Lohmayer7,8, Stefan Wilkening4, Tillmann Michels7, Daniel Brown9,10, Sebastiaan Vanuytven6,9, Svetlana Mastitskaya11,12, Sean Laidlaw3, Niels Grabe11,13, Maria Pritsch14, Raffaele Fronza4, Klaus Hexel15, Steffen Schmitt15, Michael Müller-Steinhardt16, Niels Halama11,13, Christoph Domschke17, Manfred Schmidt4, Christof von Kalle4,18, Florian Schütz17, Thierry Voet3,9, Philipp Beckhove19,20.
Abstract
Regulatory CD4+ T cells (Treg) prevent tumor clearance by conventional T cells (Tconv) comprising a major obstacle of cancer immune-surveillance. Hitherto, the mechanisms of Treg repertoire formation in human cancers remain largely unclear. Here, we analyze Treg clonal origin in breast cancer patients using T-Cell Receptor and single-cell transcriptome sequencing. While Treg in peripheral blood and breast tumors are clonally distinct, Tconv clones, including tumor-antigen reactive effectors (Teff), are detected in both compartments. Tumor-infiltrating CD4+ cells accumulate into distinct transcriptome clusters, including early activated Tconv, uncommitted Teff, Th1 Teff, suppressive Treg and pro-tumorigenic Treg. Trajectory analysis suggests early activated Tconv differentiation either into Th1 Teff or into suppressive and pro-tumorigenic Treg. Importantly, Tconv, activated Tconv and Treg share highly-expanded clones contributing up to 65% of intratumoral Treg. Here we show that Treg in human breast cancer may considerably stem from antigen-experienced Tconv converting into secondary induced Treg through intratumoral activation.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33602930 PMCID: PMC7893042 DOI: 10.1038/s41467-021-21297-y
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919